In our study, we introduce Fe‐MOF/CP, a hybrid nanozyme based on Fe‐MOF, engineered for tumor ferroptosis and immunotherapy by strategically incorporating ChOx into Fe‐MOF nanoparticles. This evidence concerns the gene CP and neoplasm.